IP Library › Granted Patent US 10,106,525
Granted Patent B2
US 10,106,525 · App. 15/591,039 · Granted Oct 23, 2018

Rho kinase inhibitor BA-1049 (R) and active metabolites thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,106,525
App. No.
15/591,039
Granted
Oct 23, 2018
Kind
B2
Abstract

The disclosure provides rho kinase inhibitor BA-1049(R), an hydroxy metabolite of BA-1049(R), and adipate salts and deuterated forms thereof, useful for treating CNS disorders and injuries.

Claims (4)

1. A pharmaceutical formulation comprising a compound of the structure:

or a salt thereof.

2. The pharmaceutical formulation of claim 1 , wherein the compound is deuterated.

3. The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation comprises an adipate salt of the compound.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 14, 2024
From: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
To: NEURELIS, INC.; AEGIS THERAPEUTICS, LLC
Reel/Frame 069359/0921 →
SECURITY INTEREST Recorded Aug 6, 2021
From: NEURELIS, INC.; AEGIS THERAPEUTICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Reel/Frame 057111/0242 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2018
From: ROSEN, KENNETH M.; ABBINANTI, MATTHEW D.; RUSCHEL, JOERG; MCKERRACHER, LISA; BOND MORITZ, LISA
To: BIOAXONE BIOSCIENCES, INC.
Reel/Frame 045178/0381 →
Cited By (2)
US 12,384,759 US 12,661,363